Karen Kelly

21.4k total citations · 7 hit papers
390 papers, 14.8k citations indexed

About

Karen Kelly is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Karen Kelly has authored 390 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Pulmonary and Respiratory Medicine, 245 papers in Oncology and 76 papers in Molecular Biology. Recurrent topics in Karen Kelly's work include Lung Cancer Treatments and Mutations (209 papers), Lung Cancer Research Studies (105 papers) and Lung Cancer Diagnosis and Treatment (91 papers). Karen Kelly is often cited by papers focused on Lung Cancer Treatments and Mutations (209 papers), Lung Cancer Research Studies (105 papers) and Lung Cancer Diagnosis and Treatment (91 papers). Karen Kelly collaborates with scholars based in United States, Canada and Germany. Karen Kelly's co-authors include Paul A. Bunn, David R. Gandara, Kathy S. Albain, Roy S. Herbst, Primo N. Lara, Joan H. Schiller, John J. Crowley, Steven D. Averbuch, John Crowley and Geoffrey R. Weiss and has published in prestigious journals such as The Lancet, JAMA and Nucleic Acids Research.

In The Last Decade

Karen Kelly

379 papers receiving 14.4k citations

Hit Papers

Efficacy of Gefitinib, an... 2001 2026 2009 2017 2003 2001 2017 2014 2019 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
    2003 2.1k citations Roy S. Herbst, Karen Kelly et al. profile →
  2. Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
    2001 923 citations Karen Kelly, Paul A. Bunn et al. Journal of Clinical Oncology profile →
  3. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
    2017 466 citations Karen Kelly, Thomas E. Stinchcombe et al. Journal of Clinical Oncology profile →
  4. Twenty years post‐NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial accrual
    2014 335 citations Primo N. Lara, Karen Kelly et al. profile →
  5. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
    2019 319 citations Karen Kelly, Haeseong Park et al. profile →
  6. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
    2017 226 citations Karen Kelly et al. profile →
  7. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
    2022 128 citations Karen L. Reckamp, Mary W. Redman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Kelly United States 59 9.4k 8.3k 3.4k 1.7k 1.3k 390 14.8k
Mary O’Brien United Kingdom 52 12.1k 1.3× 8.8k 1.1× 2.3k 0.7× 2.2k 1.3× 1.6k 1.2× 273 17.2k
Hye Ryun Kim South Korea 48 6.1k 0.7× 5.9k 0.7× 3.1k 0.9× 1.8k 1.1× 834 0.6× 338 10.7k
Roy M. Bremnes Norway 59 6.3k 0.7× 4.2k 0.5× 4.4k 1.3× 2.4k 1.4× 2.5k 1.9× 229 13.0k
Primo N. Lara United States 60 7.0k 0.7× 8.5k 1.0× 6.0k 1.8× 3.5k 2.1× 1.5k 1.1× 458 16.3k
Chandra P. Belani United States 64 13.4k 1.4× 14.2k 1.7× 6.3k 1.9× 2.4k 1.4× 1.7k 1.3× 458 22.0k
Nasser H. Hanna United States 50 7.0k 0.7× 7.1k 0.9× 2.7k 0.8× 1.1k 0.7× 1.4k 1.1× 301 11.4k
John J. Crowley United States 59 8.0k 0.8× 8.8k 1.0× 3.9k 1.1× 1.8k 1.0× 2.0k 1.5× 195 17.8k
Eitan Amir Canada 57 8.8k 0.9× 3.9k 0.5× 2.6k 0.8× 3.6k 2.1× 2.0k 1.5× 416 15.4k
Stefan Sleijfer Netherlands 61 7.1k 0.8× 4.7k 0.6× 4.2k 1.3× 3.5k 2.1× 1.0k 0.8× 379 13.6k
Alicia Samuels United States 8 4.7k 0.5× 3.5k 0.4× 3.4k 1.0× 1.6k 0.9× 2.1k 1.6× 8 11.4k

Countries citing papers authored by Karen Kelly

Since Specialization
Citations

This map shows the geographic impact of Karen Kelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Kelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Kelly more than expected).

Fields of papers citing papers by Karen Kelly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Kelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Kelly. The network helps show where Karen Kelly may publish in the future.

Co-authorship network of co-authors of Karen Kelly

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Kelly. A scholar is included among the top collaborators of Karen Kelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Kelly. Karen Kelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tsao, Anne S., Marianna Koczywas, Jonathan W. Riess, et al.. (2024). S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 8110–8110. 3 indexed citations
3.
Chen, Zexiang, Karen Kelly, Xiaolong Dong, et al.. (2023). In Vivo Prime Editing by Lipid Nanoparticle Co-Delivery of Chemically Modified pegRNA and Prime Editor mRNA. PubMed. 2(6). 490–502. 15 indexed citations
4.
Nelson, Blessie Elizabeth, Rahul A. Sheth, Karen Kelly, et al.. (2023). First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). e14584–e14584. 7 indexed citations
5.
Padda, Sukhmani K., Mary W. Redman, David E. Gerber, et al.. (2023). ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). TPS9143–TPS9143. 2 indexed citations
6.
Chen, Zexiang, Suet‐Yan Kwan, Aamir Mir, et al.. (2023). A Fluorescent Reporter Mouse for In Vivo Assessment of Genome Editing with Diverse Cas Nucleases and Prime Editors. The CRISPR Journal. 6(6). 570–582. 3 indexed citations
7.
Mack, Philip C., Jieling Miao, Mary W. Redman, et al.. (2022). Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403). Clinical Cancer Research. 28(17). 3752–3760. 31 indexed citations
8.
Liu, Pengpeng, Ogooluwa Ojelabi, Xin D. Gao, et al.. (2022). Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector. PubMed. 1(3). 285–299. 43 indexed citations
9.
Camidge, D. Ross, Daniel Morgensztern, Rebecca S. Heist, et al.. (2021). Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma. Clinical Cancer Research. 27(21). 5781–5792. 60 indexed citations
10.
Leighl, Natasha B., Mary W. Redman, Naiyer A. Rizvi, et al.. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer. 9(8). e002973–e002973. 38 indexed citations
11.
Li, Tianhong, et al.. (2019). Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non–small-cell Lung Cancer. Clinical Lung Cancer. 21(1). e15–e20. 6 indexed citations
12.
Kim, Edward S., Karen Kelly, Luis Paz‐Ares, et al.. (2018). Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study. Clinical Cancer Research. 24(22). 5543–5551. 17 indexed citations
13.
Tomlinson, Benjamin, James A. Thomson, John S. Bomalaski, et al.. (2015). Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research. 21(11). 2480–2486. 66 indexed citations
14.
Fahrmann, Johannes F., Kyoungmi Kim, Brian C. DeFelice, et al.. (2015). Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer. Cancer Epidemiology Biomarkers & Prevention. 24(11). 1716–1723. 59 indexed citations
15.
Keith, Robert L., Patrick J. Blatchford, John Kittelson, et al.. (2011). Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers. Cancer Prevention Research. 4(6). 793–802. 72 indexed citations
16.
Kelly, Karen, Kari Chansky, Laurie E. Gaspar, et al.. (2008). Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023. Journal of Clinical Oncology. 26(15). 2450–2456. 421 indexed citations
17.
Pérez-Soler, Román, Jean Pierre Delord, Allan C. Halpern, et al.. (2005). HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. The Oncologist. 10(5). 345–356. 215 indexed citations
18.
Garg, Kavita, Robert L. Keith, Tim Byers, et al.. (2002). Randomized Controlled Trial with Low-Dose Spiral CT for Lung Cancer Screening: Feasibility Study and Preliminary Results. Radiology. 225(2). 506–510. 74 indexed citations
19.
Kelly, Karen, Edwin L. Cooper, & David A. Raftos. (1993). Cytokine-Like Activities of a Humoral Opsonin from the Solitary Urochordate Styela Clava. ZOOLOGICAL SCIENCE. 10(1). 57–64. 14 indexed citations
20.
Kelly, Karen. (1992). Purification and characterization of a humoral opsonin from the Styela clava.. Comparative Biochemistry and Physiology. 103. 749–753. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary O’Brien Breakdown of academic impact, for papers by Hye Ryun Kim Breakdown of academic impact, for papers by Roy M. Bremnes Breakdown of academic impact, for papers by Primo N. Lara Breakdown of academic impact, for papers by Chandra P. Belani Breakdown of academic impact, for papers by Nasser H. Hanna Breakdown of academic impact, for papers by John J. Crowley Breakdown of academic impact, for papers by Eitan Amir Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Alicia Samuels
Rankless by CCL
2026